NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-29 17:41இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 Net Profit at ₹12.65 Lakh on Revenue of ₹155 Lakh; EPS at ₹0.50
Colinz Laboratories reported Q2 FY27 revenue from operations of ₹155.00 lakh (₹1.55 crore), up 11.7% YoY from ₹138.80 lakh. Net profit for the quarter stood at ₹12.65 lakh compared to ₹14.05 lakh in Q2 FY26, reflecting a 10% YoY decline. Sequentially, PAT normalized from ₹240.12 lakh in Q1 FY27, which was heavily boosted by a one-off exceptional item of ₹276.33 lakh. For the first half (H1 FY27), total revenue reached ₹279.09 lakh with a PAT of ₹252.77 lakh.
உச்சம் நம்பிக்கை
என்ன மாறியதுColinz Laboratories declared its unaudited quarterly financial results for Q2 ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates modest top-line growth of 11.7% YoY, but shows normalized operating profitability following a large exceptional gain in the previous quarter.
Revenue from Operations (Q2): 155.00 LakhsNet Profit (Q2): 12.65 LakhsEPS (Q2): Rs. 0.50Total Cash and Bank Balances: 1127.25 Lakhs
📅 குறுகிய காலம்Earnings show operational stability with minimal revenue expansion; market reaction is likely to remain muted given flat YoY earnings.
📈 நீண்ட காலம்Limited; company operates at a micro-cap scale with core quarterly revenue remaining around ₹1.5 crore.
⚠ அபாய எச்சரிக்கைகள்
High dependence on non-operational items in prior periods
Small operational scale and micro-cap liquidity constraints
👀 கவனிக்க வேண்டியவை
Track core operational profit margins and revenue growth in upcoming quarters without exceptional asset sale gains.
₹54 Open Offer for 26% Stake in Colinz Laboratories: Reminder Advertisement Issued
The Dugar family (Acquirers) has issued a reminder advertisement for their open offer to acquire 6,54,966 shares, representing a 26% stake in Colinz Laboratories. The offer price is fixed at ₹54 per share, totaling ₹3.54 Cr, which is approximately 17.7% of the company's current market capitalization of ₹20 Cr. Notably, the offer price is at a significant discount of approximately 32% to the current market price of ₹79.7. This mandatory offer follows a shift in the promoter holding structure, which recently decreased from 66% to 50.6%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe acquirers have issued a formal reminder advertisement as part of the regulatory timeline for their mandatory open offer to public shareholders.
ஏன் இது முக்கியம்This represents a potential change in control or consolidation of ownership in a micro-cap pharmaceutical company with a market cap of only ₹20 Cr.
Offer Price: ₹54Stake Offered: 26%Total Offer Value: ₹3.54 கோடிOffer Value vs Market Cap: ~17.7%Current Market Price: ₹79.7
📅 குறுகிய காலம்The stock may see limited impact from the offer itself since the offer price is well below the market price, but volatility may persist due to the low market cap.
📈 நீண்ட காலம்The long-term impact depends on the new acquirers' ability to scale the business, which currently has a small TTM revenue of ₹6 Cr and OPM of 6.5%.
⚠ அபாய எச்சரிக்கைகள்
Offer price is at a steep discount to market price
Micro-cap stock with low liquidity
Potential management transition risks
👀 கவனிக்க வேண்டியவை
Monitor the completion of the open offer and any subsequent changes in management or business strategy. Given the offer price is significantly below the current market price, retail shareholders are unlikely to find the offer attractive for tendering shares.
₹54 Open Offer for 26% Stake in Colinz Laboratories by Dugar Family
Annjana Dugar, Likhitta Dugar, and Antariksh Dugar (the Acquirers) have announced an open offer to acquire up to 6,54,966 shares of Colinz Laboratories, representing 26% of the voting share capital. The offer price is set at ₹54 per share, which is a significant discount to the current market price of ₹81.7. The total offer size is valued at approximately ₹3.54 crore. This follows a recent decline in promoter holding from 66.0% in March 2026 to 50.6% in June 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved to the next regulatory stage of a mandatory open offer with the publication of the offer opening public announcement and corrigendum.
ஏன் இது முக்கியம்This transaction indicates a potential consolidation of control by the Dugar family. For a micro-cap company with a ₹21 Cr market cap, a 26% stake acquisition is highly material and could lead to changes in management or strategic direction.
Offer Price: ₹54Current Market Price: ₹81.7Offer Size (Shares): 6,54,966Total Offer Value: ₹3.54 கோடிOffer Value vs Market Cap: ~16.8%Stake Offered: 26%
📅 குறுகிய காலம்The stock may experience volatility as the market reacts to the low offer price. The gap between the market price and the offer price suggests limited immediate incentive for retail investors to tender shares.
📈 நீண்ட காலம்The long-term impact depends on the final shareholding structure post-offer and whether the new controlling group implements operational changes to improve the current 6.5% operating margins.
⚠ அபாய எச்சரிக்கைகள்
Offer price is at a significant discount to market price
Low liquidity in micro-cap stock (₹21 Cr M-Cap)
Potential for low acceptance ratio
👀 கவனிக்க வேண்டியவை
Investors should monitor the official offer opening and closing dates. Given the offer price (₹54) is substantially lower than the current market price (₹81.7), the acceptance ratio from public shareholders may be low unless the market price corrects.
₹54 Open Offer for 26% Stake in Colinz Laboratories by Dugar Family
The Dugar family (Acquirers) has issued a formal Letter of Offer to acquire up to 6,54,966 shares, representing 26% of the voting capital of Colinz Laboratories. The offer price is set at ₹54 per share, which is a significant 32.5% discount to the current market price of ₹80. The total consideration for the offer amounts to ₹3.54 crore, representing approximately 17.7% of the company's current market capitalization of ₹20 crore. This follows a recent drop in promoter holding from 66.0% to 50.6% in the June 2026 quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுA formal Letter of Offer has been filed by new acquirers (the Dugar family) to take a substantial stake and control of the company.
ஏன் இது முக்கியம்A change in control in a micro-cap company (₹20 Cr M-Cap) with low margins (6.5%) could lead to a shift in business strategy or capital infusion, which is critical for a firm with only ₹6 Cr in annual revenue.
Offer Price: ₹54Current Market Price: ₹80.0Offer Size (Shares): 6,54,966Total Offer Value: ₹3.54 கோடிOffer Value vs Market Cap: 17.7%
📅 குறுகிய காலம்The stock may experience volatility as the market digests the entry of new acquirers and the low offer price relative to the current market price.
📈 நீண்ட காலம்The long-term outlook depends entirely on the new management's ability to scale the pharmaceutical business, which currently has a low ROCE of 7.2%.
⚠ அபாய எச்சரிக்கைகள்
Offer price is at a steep discount to market price
Change in management/control risk
Low liquidity in micro-cap stocks
👀 கவனிக்க வேண்டியவை
Investors should monitor the tendering period dates and the post-offer shareholding structure. Given the market price is significantly higher than the offer price, the offer is currently unattractive for tendering, but the change in control is a major event for this micro-cap company.
40th AGM Scheduled and CEO Tenure Extended for 1 Year at Colinz Laboratories
Colinz Laboratories held a board meeting on July 30, 2026, to approve the un-audited financial results for the quarter ended June 30, 2026. The board confirmed the 40th Annual General Meeting (AGM) for September 22, 2026, and set the share transfer book closure from September 15 to September 22, 2026. Key leadership decisions include the re-appointment of Mr. N. K. Menon as CEO for a one-year term and the appointment of Mrs. Vijaya Mani as a Promoter Director. New internal and secretarial auditors were also appointed for the 2026-27 financial year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its AGM timeline and extended the tenure of its current CEO by one year while adding a new promoter director to the board.
ஏன் இது முக்கியம்For a micro-cap company with a Rs 21 Cr market cap, leadership continuity and regulatory compliance are essential for maintaining investor confidence and operational stability.
CEO Tenure Extension: 1 YearAGM Date: செப்டம்பர் 22, 2026Cut-off Date: செப்டம்பர் 15, 2026சந்தை மதிப்பு: Rs 21 கோடிTTM வருவாய்: Rs 6 கோடி
📅 குறுகிய காலம்The stock may remain neutral as the announcement is primarily administrative; the actual Q1 financial performance figures will be the primary driver.
📈 நீண்ட காலம்Limited structural change; the one-year extension for the CEO suggests a short-term leadership horizon which may need monitoring for succession planning.
⚠ அபாய எச்சரிக்கைகள்
Micro-cap liquidity risk
Short-term CEO tenure extension (1 year)
👀 கவனிக்க வேண்டியவை
Investors should review the detailed Q1 FY27 financial results once the full tables are released to compare against the TTM revenue of Rs 6 Cr and check for margin improvements.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Colinz Laboratories Approves Q1 Results; Re-appoints CEO for 1-Year Term
Colinz Laboratories held its board meeting on July 30, 2026, approving the un-audited financial results for the quarter ended June 30, 2026. The board re-appointed Mr. N. K. Menon as Whole-time Director and CEO for a further one-year term effective October 1, 2026. Additionally, the company scheduled its 40th Annual General Meeting (AGM) for September 22, 2026, and appointed new internal and secretarial auditors for FY27. Mrs. Vijaya Mani was also appointed as a Promoter and Non-Executive Director.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has extended the CEO's tenure by one year and formalized the schedule for its upcoming AGM and auditor appointments.
ஏன் இது முக்கியம்For a micro-cap company with a Rs 21 Cr market cap, leadership continuity and timely financial reporting are essential for maintaining investor confidence and regulatory compliance.
CEO Tenure Extension: 1 ஆண்டுAGM Date: செப்டம்பர் 22, 2026Book Closure Period: செப். 15 to செப். 22, 2026TTM வருவாய்: Rs 6 கோடிMarket Capitalization: Rs 21 கோடி
📅 குறுகிய காலம்The stock may remain neutral as the announcement primarily covers administrative approvals and routine management extensions.
📈 நீண்ட காலம்Limited structural impact; the one-year extension for the CEO suggests a short-term leadership horizon which may need monitoring for succession planning.
⚠ அபாய எச்சரிக்கைகள்
Promoter holding decreased from 66.0% in March 2026 to 50.6% in June 2026
Micro-cap liquidity risks
Short 1-year extension for CEO
👀 கவனிக்க வேண்டியவை
Investors should review the detailed Q1 FY27 financial statements once released to assess if the company is maintaining its TTM revenue of Rs 6 Cr and OPM of 6.5%.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
